The Probable ATP Dependent RNA Helicase DDX58 pipeline drugs market research report outlays comprehensive information on the Probable ATP Dependent RNA Helicase DDX58 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Probable ATP Dependent RNA Helicase DDX58 pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.
The report also covers products from therapy areas such as Oncology, Infectious Disease, and Respiratory which include the indications Unspecified Cancer, Melanoma, Coronavirus Disease 2019 (COVID-19), Hepatitis B, and Viral Respiratory Tract Infection. It also reviews key players involved in Probable ATP Dependent RNA Helicase DDX58 targeted therapeutics development with respective active and dormant or discontinued products.
The Probable ATP Dependent RNA Helicase DDX58 pipeline targets constitutes close to ten molecules. Out of which, approximately seven molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical, and Discovery stages are 1, 4, and 2 respectively. Similarly, the universities portfolio in Preclinical comprises 3 molecule.
Probable ATP Dependent RNA Helicase DDX58 overview
RIG-I (retinoic acid-inducible gene 1) is a RIG-I-like receptor dsRNA helicase enzyme encoded by the DDX58 gene. It is involved in viral double-stranded (ds) RNA recognition and the regulation of immune response. It acts as a cytoplasmic sensor of viral nucleic acids and plays a major role in sensing viral infection and in the activation of a cascade of antiviral responses including the induction of type I interferons and proinflammatory cytokines.
For a complete picture of Probable ATP Dependent RNA Helicase DDX58’s drug pipeline, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.